Management of Intracerebral Hemorrhage

Introduction to Nimodipine

Nimodipine is a calcium channel blocker (CCB) with distinct properties and uses, having various effects on the cardiovascular system 1, 2, 3, 4, 5

The recommended dose of nimodipine for subarachnoid hemorrhage (SAH) is 60 mg (two 30 mg capsules) every 4 hours for 21 consecutive days, starting within the first 96 hours of SAH onset, as recommended by the Canadian Stroke Best Practice Recommendations and the American Heart Association/American Stroke Association 6, 7, 8
Nimodipine should be administered orally, and can be given via nasogastric tube or PEG for patients who cannot swallow capsules 6
In cases of liver dysfunction or cirrhosis, the dose should be reduced to 30 mg every 4 hours, and the patient should be monitored closely for hypotension, while elderly patients may require dose reduction due to approximately 2× higher plasma concentrations 6, 9

Nimodipine should never be administered intravenously or parenterally, as it can cause severe hypotension, with a strength of evidence classified as Class I, Level A 6
Grapefruit juice should be avoided during treatment, as it affects metabolism, and euvolemia should be maintained rather than hypervolemia or hypovolemia, with prophylactic hemodynamic augmentation not recommended 6, 10

Nimodipine reduces late cerebral ischemia and improves functional outcomes in patients with aneurysmal subarachnoid hemorrhage, with a strength of evidence classified as Class I, Level A 6, 7
Nimodipine decreases the severity of neurological deficits resulting from vasospasm and reduces the incidence of cerebral infarction by 34% and unfavorable outcomes by 40% 6, 7, 8, 11

Blood pressure control should target systolic BP <160 mmHg before aneurysm securing, and consider elevating systolic BP to reduce DCI progression after securing and with symptomatic vasospasm, as recommended by the guidelines 6, 7
Excessive blood pressure reduction with CCBs can compromise cerebral perfusion, leading to harmful outcomes, and the American Heart Association recommends avoiding short-acting dihydropyridines like immediate-release nifedipine in acute stroke settings 1, 2

The American Heart Association/American Stroke Association strongly recommends early initiation of enteral nimodipine to prevent delayed cerebral ischemia and improve functional outcomes after aneurysmal SAH, with Class I, Level A evidence 6, 7
The Canadian Stroke Best Practice Recommendations specify nimodipine should be continued for 14 to 21 days, and initiated within 96 hours after subarachnoid hemorrhage onset 8
The American College of Cardiology gives a Class III recommendation (No Benefit) for CCBs in heart failure with reduced ejection fraction, as they may worsen outcomes due to negative inotropic effects 3

The European Stroke Organisation guidelines do not recommend nimodipine for the management of intracerebral hemorrhage 12
The Neurocritical Care Society guidelines for reversal of antithrombotics in intracerebral hemorrhage do not mention nimodipine 13
There are no guidelines from reputable organizations recommending nimodipine for primary intracerebral hemorrhage 13, 12